Lilly's weight-loss drugs outperform competitors in clinical trials

Statements (7)

1. ▲ Bullish

   Lilly's experimental combined drug for weight loss surpassed Zepbound in a direct comparative clinical trial.

   eleconomista.com.mxSep 30, 2026 15:00 UTCHigh importance
2. ▲ Bullish

   Eli Lilly and Company said its experimental EloraTZP combination produced greater weight loss than tirzepatide alone in a mid-stage trial involving 367 adults with obesity or overweight.

   breakingthenews.netSep 30, 2026 14:59 UTC
3. ▲ Bullish

   Lilly's new drug added to Zepbound helped people lose up to 23% of their weight.

   marketwatch.comSep 30, 2026 14:32 UTCHigh importance
4. ▲ Bullish

   Lilly's eloraTZP combination achieved the best-ever weight loss of 23.3% in patients with obesity and diabetes

   endpoints.newsSep 30, 2026 14:15 UTCHigh importance
5. ● Neutral

   Patients switching from Novo's Wegovy injections to the pill are losing weight in real-world studies

   cnbc.comSep 30, 2026 09:45 UTC
6. ● Neutral

   Lilly's experimental drug for diabetes cuts weight by 21% in a clinical trial

   reuters.comSep 29, 2026 22:15 UTC
7. ● Neutral

   Eli Lilly and Co. reported that Zepbound delivered greater weight loss than Wegovy in an indirect treatment comparison

   breakingthenews.netSep 29, 2026 11:32 UTC